Skip to main content
Veterinary Medicines

Versican Plus P lyophilisate and solvent for suspension for injection for dogs

Authorised
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live

Product identification

Medicine name:
Versican Plus P lyophilisate and solvent for suspension for injection for dogs
Versican Plus P λυοφιλοποιημένο υλικό και διαλύτης για ενέσιμο εναιώρημα για σκύλους
Active substance:
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
    19953.00
    tissue culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD01
Authorisation status:
  • Valid
Authorised in:
  • Cyprus
Package description:
  • (ID2): 1 Box with 50 Vial (Glass) with 1 Dose and 50 Vial (Glass) with 1 ml (50.0 Dose, 50.0ml)
  • (ID1): 1 Box with 25 Vial (Glass) with 1 Dose and 25 Vial (Glass) with 1 ml (25.0 Dose, 25.0 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Zoetis Hellas S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment
Authorisation number:
  • CY00645V
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0265/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • France
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Luxembourg
  • Malta
  • Romania
  • Slovenia
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

English (PDF)
Published on: 24/05/2023
Download
Greek (PDF)
Published on: 17/10/2023

Summary of Product Characteristics

English (PDF)
Published on: 14/02/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."